Centurion Shores Up Biotech Outfit With $10M Investment
Centurion is taking a stake in Amarantus as it works to develop therapies based on a protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor. MANF is a disease-modifying protein that corrects apoptosis, or cell death, that characterizes Parkinson’s and ischemic heart disease, the biotech company said in a statement.
“Centurion is pleased to partner with Amarantus to unlock...
To view the full article, register now.